PT  - JOURNAL ARTICLE
AU  - Ying Xue
AU  - Yuting Gao
AU  - Fanling Meng
AU  - Liang Luo
TI  - Recent progress of nanotechnology-based theranostic systems in cancer treatments
AID  - 10.20892/j.issn.2095-3941.2020.0510
DP  - 2021 May 01
TA  - Cancer Biology and Medicine
PG  - 336--351
VI  - 18
IP  - 2
4099  - http://www.cancerbiomed.org/content/18/2/336.short
4100  - http://www.cancerbiomed.org/content/18/2/336.full
SO  - Cancer Biol Med2021 May 01; 18
AB  - Theranostics that integrates therapy and diagnosis in one system to achieve accurate cancer diagnosis and treatment has attracted tremendous interest, and has been recognized as a potential breakthrough in overcoming the challenges of conventional oncotherapy. Nanoparticles are ideal candidates as carriers for theranostic agents, which is attributed to their extraordinary physicochemical properties, including nanoscale sizes, functional properties, prolonged blood circulation, active or passive tumor targeting, specific cellular uptake, and in some cases, excellent optical properties that ideally meet the needs of phototherapy and imaging at the same time. Overall, with the development of nanotechnology, theranostics has become a reality, and is now in the transition stage of “bench to bedside.” In this review, we summarize recent progress on nanotechnology-based theranostics, i.e., nanotheranostics, that has greatly assisted traditional therapies, and has provided therapeutic strategies emerging in recent decades, as well as “cocktail” theranostics mixing various treatment modalities.